Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

OPTILATER: optimal long-term survival after cancer - a cross-sectional study protocol for a quantitative survey on the care situation of long-term cancer survivors in Germany.

BMC cancer·2025
Same author

Exploring long-term cancer survivors' care experiences and unmet needs: protocol for a qualitative study.

BMC cancer·2024
Same author

Correction to: No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease.

Bone marrow transplantation·2021
Same author

Treatment-related fertility impairment in long-term female childhood, adolescent and young adult cancer survivors: investigating dose-effect relationships in a European case-control study (PanCareLIFE).

Human reproduction (Oxford, England)·2021
Same author

No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease.

Bone marrow transplantation·2021
Same author

Comprehensive assessments and related interventions to enhance the long-term outcomes of child, adolescent and young adult cancer survivors - presentation of the CARE for CAYA-Program study protocol and associated literature review.

BMC cancer·2020
Same journal

The ethical obligation to use positive trial results.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Lorlatinib: The Crown Jewel of ALK Inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

TROP2-Directed Antibody Drug Conjugates: New First-Line Treatment for All Patients with Advanced Triple-Negative Breast Cancer?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

When artificial intelligence learns to abstain: towards clinically responsible diagnostic support in liver pathology.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

PRMT5 inhibitors in MTAP loss NSCLC with actionable genomic alterations: a new kid on the block?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Refining decision making in hormone receptor-positive early-stage breast cancer: moving from static to dynamic.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
See all related articles

Related Experiment Video

Updated: May 10, 2026

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Renal Ewing tumors.

S Zöllner1, U Dirksen, H Jürgens

  • 1Department of Pediatric Hematology and Oncology, University Hospital, Muenster, Germany.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|June 14, 2013
PubMed
Summary
This summary is machine-generated.

Renal Ewing sarcoma/primitive neuroectodermal tumor (ES/PNET) is rare but treatable with conventional ES protocols. Early diagnosis and guideline-adapted therapy improve outcomes for this rare kidney cancer.

Keywords:
Ewing's sarcomaPNETkidneyoutcome

More Related Videos

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
09:58

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

Related Experiment Videos

Last Updated: May 10, 2026

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
09:58

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

Area of Science:

  • Oncology
  • Pediatric Oncology
  • Rare Cancers

Background:

  • Renal Ewing sarcoma/primitive neuroectodermal tumor (ES/PNET) is an exceptionally rare malignancy.
  • Clinical presentation is often nonspecific, including abdominal pain, palpable mass, and hematuria.
  • Diagnostic feasibility has improved with molecular detection of the EWS/ETS translocation.

Purpose of the Study:

  • To analyze outcomes for patients with renal ES/PNET treated within established Ewing sarcoma study protocols.
  • To evaluate the efficacy of current treatment strategies for this rare renal tumor.

Main Methods:

  • Retrospective analysis of 24 patients with primary renal ES/PNET from the German GPOH Ewing sarcoma trials (1980-2009).
  • Inclusion of a Medline search for additional renal ES/PNET cases.
  • Median observation time of 3.71 years.

Main Results:

  • Median patient age was 24.9 years, with 37.5% presenting with metastases.
  • Tumor thrombi in renal vessels occurred in 56.2%; EWS/ETS translocation confirmed in 90.9%.
  • Three-year overall survival (OS) was 0.80 and event-free survival (EFS) was 0.66 with combined chemotherapy and local control.

Conclusions:

  • Renal ES/PNET warrants consideration in the differential diagnosis of renal tumors.
  • Patients with renal ES/PNET demonstrate responsiveness to standard ES treatments.
  • Emphasis on accurate diagnosis and adherence to guideline-based therapy is crucial for optimal patient management.